Stay updated with breaking news from Scientific Task. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today announced it will host a virtual event on the use of KIN001 for the treatment of COVID-19 on Wednesday, August 24 at 2:00 pm ...
Kinarus Therapeutics Holding AG / Key word(s): Miscellaneous Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19 22-Aug-2022 / 07:06 CET/CEST Release of an ad hoc announcement
KIN001 has synergistic antiviral, anti-inflammatory activity, and anti-fibrotic mechanismsPhase 2 trials of KIN001 in hospitalized and ambulatory COVID-19 patients ongoingInterim data from Phase 2 study
KIN001 has synergistic antiviral, anti-inflammatory activity, and anti-fibrotic mechanismsPhase 2 trials of KIN001 in hospitalized and ambulatory COVI
ISLAMABAD: A prominent public health expert and member of the Scientific Task Force on COVID-19, Prof Dr Javed Akram has said that the sudden decrease in coronavirus cases in the country was due to...